Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Yissum, the technology transfer company of the Hebrew University of Jerusalem has licensed an orally–available small molecule for several biological indications including the treatment of neurodegenerative diseases to Eucalyptus.
Subscribe to our email newsletter
Under the terms of the agreement, Eucalyptus has acquired worldwide exclusive rights to develop and commercialize the molecule and Yissum together with Ramot, the technology transfer company of Tel Aviv University, and Mor Research Applications, the technology transfer company of Clalit Health Services, will receive upfront payments, milestone payments in accordance with development progress and royalties from sales of final products.
The molecule, N-acetylcysteine amide (AD4), is an antioxidant for the prevention and treatment of Parkinson’s, Alzheimer’s, multiple sclerosis and other neurodegenerative diseases that are linked to oxidative stress, and also has broader applications in biology.
Ashley Bush, chief Scientific officer of Eucalyptus, said: “We are excited to be able to progress the pioneering work of our Israeli collaborators towards commercialization.”